Physician profile
Michael S Ensor
NPI 1679501019
$1,730.07
in general payments reported to CMS, 2019-2025
11 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2022: $64.03 · 2023: $93.13 · 2024: $339 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.16 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $807.41 | 2019 | |
| Harrow Eye, LLC | $357.41 | 2023-2024 | Iheezo, Tobradex St, Flarex |
| Biotissue Holdings INC. | $129.62 | 2025 | |
| Mallinckrodt Hospital Products INC. | $127.50 | 2025 | Acthar |
| Shire North American Group INC | $84.63 | 2019 | |
| Abbvie INC. | $64.03 | 2022 | |
| Alcon Vision LLC | $61.98 | 2023-2025 | Argos, Tryptyr, Total30 |
| Tarsus Pharmaceuticals, INC. | $34.32 | 2025 | Xdemvy |
| Thea Pharma INC. | $29.22 | 2025 | Iyuzeh |
| Bausch & Lomb Americas INC. | $17.84 | 2023 | Miebo |
| Carl Zeiss Meditec USA, INC. | $16.11 | 2024 | Clarus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ensor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.